Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of HRS-7249 in Hypertriglyceridemia
NCT07799688Phase 2Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7249 in hypertriglyceridemia, sponsored by Fujian Shengdi Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
HRS-7249
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07799688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799688.